Cite
APA Citation
Fayette, J. (n.d.). 90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03). Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100098459706.0x000030